


Deferasirox (Fe<sup>3+</sup> chelate)**Chemical Properties**

|                   |  |
|-------------------|--|
| CAS No.:          | 554435-83-5  |
| Formula:          | C <sub>21</sub> H <sub>12</sub> FeN <sub>3</sub> O <sub>4</sub>        |
| Molecular Weight: | 426.18   |
| Appearance:       | N/A  |
| Storage:          | 0-4°C for short term (days to weeks), or -20°C for long term (months). |

**Biological Description**

|                            |   |
|----------------------------|---|
| Description                | Deferasirox Fe <sup>3+</sup> + chelating agent is a well-designed oral iron chelating agent. Its main use is to reduce chronic iron overload in patients receiving long-term blood transfusions (such as thalassemia and other chronic anemia).   |
| Targets(IC <sub>50</sub> ) | Others: None  |
| In vitro                   | Deferasirox is the first oral drug approved for this purpose in the United States. The half-life of deferasirox is between 8 and 16 hours, allowing administration once a day. The two molecules of deferasirox are able to bind to one iron atom, which is then eliminated by fecal excretion. Because of its low molecular weight and high lipophilicity, the drug can be taken orally, which is different from deferoxamine, which must be administered by intravenous injection (intravenous infusion). |

**Solubility Information**

|            |  |
|------------|--|
| Solubility | DMSO: 50 mg/mL (117.32 mM)<br>( < 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

## Preparing Stock Solutions

|       | 1mg      | 5mg       | 10mg      |
|-------|----------|-----------|-----------|
| 1 mM  | 2.346 mL | 11.732 mL | 23.464 mL |
| 5 mM  | 0.469 mL | 2.346 mL  | 4.693 mL  |
| 10 mM | 0.235 mL | 1.173 mL  | 2.346 mL  |
| 50 mM | 0.047 mL | 0.235 mL  | 0.469 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Yang LP, Keam SJ, Keating GM. Deferasirox : a review of its use in the management of transfusional chronic iron overload. *Drugs*. 2007;67(15):2211-30.
2. Kontoghiorghe GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. *Expert Opin Drug Saf*. 2010 Jul;9(4):633-41.
3. Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. *Expert Opin Drug Metab Toxicol*. 2012 Jan;8(1):123-34.
4. Donnelly JP, Lahav M. Deferasirox as adjunctive therapy for mucormycosis. *J Antimicrob Chemother*. 2012 Mar;67(3):519-20.
5. Lui GY, Obeidy P, Ford SJ et al. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. *Mol Pharmacol*. 2012 Oct 16. [Epub ahead of print]

**Inhibitors · Natural Compounds · Compound Libraries**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.**

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481